Interleukin-6 (IL-6) in patients with Behçet's disease

Yamakawa, Yuko; Sugita, Yasuyuki; Nagatani, Tetsuya; Takahashi, Satoshi; Yamakawa, Tadashi; Tanaka, Shun‐ichi; Nakamura, Satoshi; Ohno, Shigeaki; Sekihara, Hisahiko; Okuda, Kenji; Nakajima, Hiroshi

doi:10.1016/0923-1811(95)00439-4

Cited by 54 publications

(40 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 Sayi nalp et al simiarly fo und that se rum le vels of IL-1 be ta, IL-2 and IL-6 in the pa ti ents with BD we re si mi lar to the con trol gro up, but se rum le vels of sIL-2R and TNF-α we re hig her in pa ti ents with BD com pa red to con trols. 20 Our fin dings on se rum IL-6 le vels are inconsistent with tho se of Me ge, Turan, Ya ma ka wa, Na wa ta, Ham za o u i, Eve rek li og lu, Bar dak, Adam, Ak de niz et al, however they are consistent with tho se of al-Da la an, and Sa yi nalp et al 8,[11][12][13][14][15][16][17][18][19][20] The only study in li te ra tu re in which se rum adi no pec tin le vel is in ves ti ga ted in BD was per formed by Oguz et al 22 In this study, se rum adi no pectin le vels we re not sig ni fi cantly dif fe rent in BD in com pa ri son to the he althy con trol gro up. The ir pati ent gro up ma ni fes ted si mi la ri ti es to our pa ti ents be ca u se 86.8% of the pa ti ents used colc hi ci ne, 2.6% used ste ro id and 5.3% used im mu no sup res si ves.…”

Section: Discussionsupporting

confidence: 49%

“…12 Yama ka wa et al exa mi ned the le vels of IL-6 in plasma and su per na tants of pe rip he ral blo od mo no nuc le ar cells (PBMC) from BD pa ti ents and he althy con trols using a sen si ti ve ELI SA. 13 The IL-6 con cen tra ti ons in cul tu re su per na tants of pa ti ents with ac ti ve BD we re sig ni fi cantly high when compa red to pa ti ents with inac ti ve di se a se and the controls. They re por ted that IL-6 might play a ro le in the pat ho ge ne sis of BD.…”

Section: Discussionmentioning

confidence: 99%

“…Many in vi vo stu di es ha ve de mons tra ted that TNF-α, IL-1, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IL-18, G-CSF and IFN-γ were all im por tant com po nents of the pro inf lam ma tory res pon se in BD. 8,[11][12][13][14][15][16][17][18] Me ge et al fo und that the spon ta ne o us sec re ti on of TNF-α, Turkiye Klinikleri J Med Sci 2010;30 (6) IL-6 and IL-8 by mo nocy tes was sig ni fi cantly incre a sed in pa ti ents with ac ti ve BD. 11 Tu ran et al re por ted that IL-10 and IL-12 were in cre a sed in BD and IL-12 had a cor re la ti on with ac ti va ti on.…”

Section: Discussionmentioning

confidence: 99%

“…9,10 Stu di es on cyto ki ne pro fi le in BD have yielded conf lic ting re sults. 8,[11][12][13][14][15][16][17][18][19][20] Adi po nec tin is an adi pocy to ki ne which was de fi ned first and it is the major pro te in produced by the adi pocy tes. It is a cen tral re gu la tory pro te in con trol ling li pid and car bohy dra te me ta bo lism in many physi o lo gic path ways and it me di a tes va ri ous vas cu lar pro ces ses.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Serum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behçet’s Disease

Etem¹,

Yildirmak²,

Önalan³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

A AB BS S T TR RA AC CT T O Ob b j je ec c t ti i v ve e: : Beh çet's di se a se (BD) is a chro nic syste mic inf lam ma tory di se a se and its etio pat ho ge ne sis still re ma ins unk nown. Cyto ki nes play a ro le in im mu ne res pon se and inf lam ma tory re ac ti ons. The aim of this study is to de ter mi ne the le vels of pro inf lam ma tory cyto ki ne in ter le ukin-6 (IL-6) and an ti-inf lam ma tory cyto ki ne adi po nec tin in the sera of pa ti ents with BD and to assess their im por tan ce as bi o lo gi cal mar kers for di se a se ac ti vity. M Ma a t te e r ri i a al l a an nd d M Me et t h ho od ds s: : Forty-four BD pa ti ents [19 ma les, 25 fe ma les, age: 35.65 ± 10.84 yrs (me an ± stan dart de vi a ti on) (SD)] and 25 he althy con trols (10 ma les, 15 fe ma les, age: 29.80 ± 8.20 yrs) we re inc lu ded in the study. Pa ti ents we re divided into ac ti ve or inac ti ve gro ups ac cor ding to the ir cli ni cal and la bo ra tory fin dings (acti ve, n= 21; inac ti ve, n= 23). We de ter mi ned se rum IL-6 le vels using the che mi lu mi nes cen ce method, and se rum adi po nec tin le vels by ELI SA met hod. Re sults we re ex pres sed as me an ± stan dard er ror (SE). R Re e s su ul lt ts s: : Se rum le vels of IL-6 and adi po nec tin in BD pa ti ents (n= 44) (5.24 ± 0.84 pg/mL; 22.31 ± 1.71 µg/mL, res pec ti vely) we re si mi lar to the con trol gro up (n= 25) (4.59 ± 1.01 pg/mL; 21.68 ± 1.91 µg/mL, res pec ti vely). No sig ni fi cant dif fe ren ce was fo und in IL-6 and adi po nec tin le vels bet we en the ac ti ve (n= 21), inac ti ve (n= 23) and con trol (n= 25) gro ups. C Co on nc c l lu u s si i o on n: : In pa ral lel with the pre sen ce of inf lam ma ti on and in cre a sed CRP, eryt hrocy te se di men ta ti on ra te and white blood cell co unt, hig her IL-6 and lo wer adi po nec tin le vels were ex pec ted in ac ti ve BD pa ti ents com pa red to the con trols. However, they were found to be si mi lar in all gro ups. We conc lu de that on go ing an ti-inf lam ma tory tre at ment sho uld be ta ken in to con si de ra ti on whi le in ter pre ting the cyto ki ne levels in the se pa ti ents. K Ke ey y W Wo or rd ds s: : Beh cet's syndro me; adi po ki nes; in ter le u kin-6 Ö ÖZ ZE ET T A Am ma aç ç: : Beh çet has ta lı ğı (BH), kro nik sis te mik inf la ma tu ar bir has ta lık olup eti yo pa to ge ne zi he nüz bi lin me mek te dir. İmmun ce vap ve inf la ma tu var sü reç iliş ki sin de si to kin ler rol oy na mak tadır lar. Bu ça lış ma nın ama cı, BH'lı has ta la rın se rum la rın da pro-inf la ma tu ar bir si to kin olan IL-6 ile an ti-inf la ma tu ar si to kin olan adi po nek ti nin se vi ye le ri ni öl çe rek, bun la rın has ta lı ğın ak ti vi te sin de bi yo lo jik be lir teç ola rak et ki le ri ni be lir le mek tir. G Ge e r re eç ç v ve e Y Yö ön n t te em m l le er r: : Ça lış ma ya 44 BH'lı has ta (19 er kek, 25 ka dın, yaş or ta la ma sı 35.65 ± 10 yıl) ve kon trol gru bu ola rak da 25 sağ lık lı ki şi (10 er kek, 15 ka dın, yaş or ta la ma sı 29.80 ± 8.20 yıl) alın mış tır. Has ta lar kli ni...

show abstract

Section: Discussionsupporting

confidence: 49%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Serum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behçet’s Disease

Etem¹,

Yildirmak²,

Önalan³

et al. 2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

show abstract

“…Several studies have shown higher levels of serum IL6 in active BD compared to inactive BD and HC [71,89,90], and interestingly in neuro-BD patients, IL6 was noted to be markedly elevated in the cerebrospinal fluid (CSF), but not in the sera [91,92]. Blockage of IL6 signaling with tocilizumab in BD patients despite looking promising in the treatment of neuro-BD [55][56][57][58] has revealed mixed results for non-neurological manifestations [58,59,93,94] and is currently undergoing further evaluation in controlled clinical trials.…”

Section: Interleukin-6 (Il6)mentioning

confidence: 99%

Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

Adeeb¹,

Khan²,

Stack³

et al. 2017

Behcet's Disease

View full text Add to dashboard Cite

Behçet's disease (BD) is a type of vasculitis with many distinctive clinical manifestations and multifactorial immunopathogenesis. The cause of BD remains unknown, but it has been postulated that in a genetically predisposed or susceptible population, exogenous agents trigger the dysregulation of both autoinflammatory and autoimmune responses resulting in multisystem vasculitis. There are robust ongoing efforts across the globe to elucidate and identify signature markers to improve and assist in rapid diagnosis of the disease and to tailor the best therapy accordingly. While association of human leukocyte antigen (HLA)-B * 51 (B * 51:01 subtype) allele is well recognized as the strongest genetic susceptibility gene so far among genetically predisposed BD patients, further investigations using the latest technology have led to the identification of several novel single nucleotide polymorphisms (SNPs) and other associated genes involved in the pathogenesis. There are several "established" cytokines known to be involved in the pathogenesis of BD, which have been further implicated in the genome-wide association studies (GWAS)-based cytokine/receptor gene loci studies, as well as numerous "novel" cytokines, which are currently being studied and identified. This chapter offers insights into current knowledge and thoughts regarding the future of biomarkers in BD.

show abstract

Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease

Ahmed

Houman

Miled

et al. 2004

Arthritis & Rheumatism

149

View full text Add to dashboard Cite

Objective. To investigate a possible pathogenic role of cytokines in Behçet's disease (BD) by focusing on the analysis of cytokine gene expression within mucocutaneous BD lesions.Methods. The study group comprised 20 patients with active BD. In this group, a set of chemokines as well as Th1 and Th2 cytokines in biopsy specimens obtained from oral and genital ulcers, pseudofolliculitis lesions, and lesions at the site of pathergy testing were studied using real-time quantitative reverse transcriptasepolymerase chain reaction.Results. We observed important increases in the expression of interleukin-8 (IL-8) (ϳ700-fold), monocyte chemoattractant protein 1 (ϳ65-fold), interferon-␥ (ϳ71-fold), and IL-12 (ϳ69-fold) messenger RNA in BD lesions compared with normal skin. Except for IL-10 (ϳ75-fold increase), Th2 cytokines (i.e., IL-4 and IL-13) were absent.Conclusion. Our data suggest a direct role of Th1 lymphocytes in the pathogenesis of mucocutaneous BD lesions.

show abstract

Interleukin-6 (IL-6) in patients with Behçet's disease

Cited by 54 publications

References 19 publications

Serum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behçet’s Disease

Serum Interleukin-6 and Adiponectin Levels in Patients with Active or Inactive Behçet’s Disease

Etiology, Immunopathogenesis and Biomarkers in Behçet’s disease

Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease

Contact Info

Product

Resources

About